Eli Lilly has reported remarkable financial results for 2024, with total revenue climbing by one-third to reach $45 billion, primarily driven by robust demand for its diabetes and weight loss medications. The pharmaceutical giant’s fourth quarter performance was particularly impressive, posting a 45% revenue increase to $13.53 billion. The company’s weight loss drugs proved to be significant growth drivers, with Mounjaro generating $3.5 billion and Zepbound contributing $1.9 billion in fourth-quarter sales. Despite production capacity constraints, the company also benefited from unexpectedly strong sales of established medications like Jardiance and Humalog, leading to a more than doubled adjusted earnings per share of $12.99 for the year.
2025 Growth Outlook
Looking ahead to 2025, Eli Lilly projects continued strong momentum with revenue expected to reach between $58 billion and $61 billion, representing potential growth of up to 35%. The company anticipates adjusted earnings per share of $22.50 to $24.00, aligning with analyst expectations
Dieser Beitrag wurde original veröffentlicht auf: link zum Beitrag
